Q2 2025 Verastem Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $5.62 (-1.75%)

Transcript 10-Q

Key Points

Positve

Verastem Inc (VSTM) secured FDA approval for their lead program ahead of schedule, marking a significant milestone.
The company successfully launched AMA fax Ninja Copa, generating $2.1 million in net product revenue within the first six weeks.
The launch strategy effectively targeted healthcare providers and ensured seamless patient access, with coverage from major insurers.
Verastem Inc (VSTM) strengthened its financial position with a $75 million private placement, ending the quarter with $164.3 million in cash equivalents and investments.
The company is advancing multiple clinical programs, including the VS 7,375 phase 128 clinical trial and RAM 301 trial, demonstrating a commitment to expanding their oncology platform.

Negative

Research and development expenses increased significantly to $24.8 million, driven by higher clinical-related expenses and drug production activities.
Selling, general, and administrative expenses rose to $20.7 million, reflecting increased commercial readiness activities.
The company reported a non-GAAP adjusted net loss of $41.4 million, compared to a $16.5 million loss in the previous year.
There is uncertainty regarding the NCCN guideline update in October, which could impact prescribing and reimbursement trends.
The launch is still in its early stages, and while initial results are promising, long-term adoption and market penetration remain uncertain.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VSTM.OQ - Verastem Inc
Q2 2025 Verastem Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the Verisimm Oncology 2nd quarter 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session.

If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad. If you would like to withdraw your question, press one again.

Thank you. I will now turn the call over to Drewlissa Vienna, Vice President, corporate communications, Investor relations, Patient advocacy. Please go ahead.

--------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.